Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Other hematologic neoplasm 3Myeloid 1

Conditions

Myelodysplastic Syndromes 163Leukemia, Myeloid, Acute 144Leukemia, Myelogenous, Chronic, BCR-ABL Positive 68Myeloproliferative Disorders 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 53Primary Myelofibrosis 48Leukemia, Myelomonocytic, Chronic 40Lymphoma, Non-Hodgkin 38Polycythemia Vera 26Leukemia 26Hodgkin Disease 25Myelodysplastic-Myeloproliferative Diseases 21Multiple Myeloma 21Hematologic Neoplasms 21Leukemia, Lymphocytic, Chronic, B-Cell 20Thrombocythemia, Essential 19Neoplasms 17Leukemia, Biphenotypic, Acute 15Anemia, Refractory, with Excess of Blasts 14Sarcoma 13Histiocytosis, Langerhans-Cell 13Glioma 13Recurrence 12Neuroblastoma 12Hematologic Diseases 12Wilms Tumor 11Rhabdoid Tumor 11Osteosarcoma 11Neuroectodermal Tumors, Primitive, Peripheral 11Medulloblastoma 11

Interventions

Razoxane 1Idarubicin 1Gemtuzumab 1Dexrazoxane 1Cytarabine 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Myeloid × 90 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡